Phase II study of preoperative concurrent chemoradiotherapy with S-1 plus bevacizumab for locally advanced resectable rectal adenocarcinoma

Oncology (Switzerland)

Volumn 88, Issue 1, 2015, Pages 49-56

  Sadahiro, Sotaro ^a   Suzuki, Toshiyuki ^a   Tanaka, Akira ^a   Okada, Kazutake ^a   Saito, Gota ^a   Kamijo, Akemi ^a   Akiba, Takeshi ^a   Kawada, Shuichi ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

Bevacizumab; Chemoradiotherapy; Phase II study; Rectal cancer; S 1

Indexed keywords

BEVACIZUMAB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; DRUG COMBINATION; MONOCLONAL ANTIBODY; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPUTER ASSISTED RADIOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PAIN; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIATION DOSE REDUCTION; RECTOVAGINAL FISTULA; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WOUND DEHISCENCE; ADENOCARCINOMA; CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECTAL NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; POSTOPERATIVE COMPLICATIONS; RECTAL NEOPLASMS; TEGAFUR;

EID: 84925283509     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000367972     Document Type: Article

References (25)

1. Willett CG, Czito BG, Bendell JC: Radiation therapy in stage II and III rectal cancer. Clin Cancer Res 2007; 13: 6903s-6908s
2. Hofheinz R-D, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13: 579-588
3. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-557
4. Schoffski P: The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 2004; 15: 85-106
5. Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamijo A, Murayama C, Akiba T, Nakayama Y: Phase I/II study of preoperative concurrent chemoradiotherapy with S-1 for locally advanced, resectable rectal adenocarcinoma. Oncology 2011; 81: 306-311
6. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR: Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-3378
7. Lee C-G, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60: 5565-5570
8. Marijnen CA, Rutten H, De Wilt H, Tesselaar ME, Nuyttens J, Remmelzwaal J, Punt CJ, Martijn H, Hospers GA, Cats A: Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer: a feasibility study of the Dutch Colorectal Cancer Group (DCCG) (abstract). J Clin Oncol 2008; 26(suppl): 15040
9. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK: Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-3026
10. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA: Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76: 824-830
11. Mandard A-M, Dalibard F, Mandard J-C, Marnay J, Henry-Amar M, Petiot J-F, Roussel A, Jacob J-H, Segol P, Samama G, Ollivier J-M, Bonvalot S, Gignoux M: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686
12. Suzuki T, Sadahiro S, Fukasawa M, Ishikawa K, Kamijo A, Yasuda S, Makuuchi H, Ohizumi Y, Murayama C: Predictive factors of tumor shrinkage and histological regression in patients who received preoperative radiotherapy for rectal cancer. Jpn J Clin Oncol 2004; 34: 740-746
13. Suzuki T, Sadahiro S, Tanaka A, Okada K, Kamata H, Kamijo A, Murayama C, Akiba T, Kawada S: Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer. Int J Radiat Oncol Biol Phys 2013; 85: 1232-1238
14. Suzuki T, Sadahiro S, Tanaka A, Okada K, Saito G, Kamijo A, Akiba T, Kawada S: Relationship between histologic response and the degree of tumor shrinkage after chemoradiotherapy in patients with locally advanced rectal cancer. J Surg Oncol 2014; 109: 659-664
15. The final results: bevacizumab safety post-marketing large cohort survey (PMS) in 2712 Japanese colorectal cancer patients. Chugai Pharmaceutical Co., Ltd. http: //chugai-pharm.jp/hc/ss/pr/safe/report/ava/index. Html
16. Sanghera P, Wong DWY, McConkey CC, Geh JI, Hartley A: Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol 2008; 20: 176-183
17. Yerushalmi R, Idelevich E, Dror Y, Stemmer SM, Figer A, Sulkes A, Brenner B, Loven D, Dreznik Z, Nudelman I, Shani A, Fenig E: Preoperative chemoradiation in rectal cancer: retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. J Surg Oncol 2006; 93: 529-533
18. Das P, Lin EH, Bhatia S, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Delclos ME, Krishnan S, Janjan NA, Crane CH: Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 2006; 66: 1378-1383
19. Kim DY, Jung KH, Kim TH, Kim D-W, Chang HJ, Jeong JY, Kim YH, Son S-H, Yun T, Hong CW, Sohn DK, Lim S-B, Choi HS, Jeong S-Y, Park J-G: Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 67: 378-384
20. Chan AK, Wong AO, Jenken DA: Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer - is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?. Int J Radiat Oncol Biol Phys 2010; 76: 1413-1419
21. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 2004; 350: 2335-2342
22. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147
23. Spigel DR, Bendell JC, McCleod M, Shipley DL, Arrowsmith E, Barnes EK, Infante JR, Burris HA III, Greco FA, Hainsworth JD: Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin Colorectal Cancer 2012; 11: 45-52
24. Velenik V, Ocvirk J, Music M, Bracko M, Anderluh F, Oblak I, Edhemovic I, Brecelj E, Kropivnik M, Omejc M: Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol 2011; 6: 105-112
25. Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A, Berardi R, Shishido J, Yoshizawa A, Mori Y, Nagayama S, Morosini P, Toi M: A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 2012; 15: 141-150